



Press Release

May 11, 2009 - Turku, Finland

Faron and Rentschler to co-operate on Traumakine® development

Faron Pharmaceuticals, Ltd. and Rentschler Biotechnologie GmbH announced today that they have agreed to initiate co-operation on interferon-beta development and supply for Faron's lead product Traumakine® that is meant to treat vascular leakage in traumatic conditions. Traumakine's active pharmaceutical ingredient (API) is the recombinant human interferon beta-1a that was first produced by Rentschler already in the 1980's.

According to the agreement Rentschler will become the solely supplier of IFN-b 1a for Faron and Faron has an exclusive right to market and sell this product globally as an intravenous product in vascular-endothelial diseases. For the first indication under this agreement, the acute lung injury (ALI) and its more severe form ARDS, Faron has obtained an orphan drug status from the EU and is also building a strong IPR position globally. Financial details of the agreement were not released.

- This co-operation allows Faron to finalize Traumakine product development for pan-European clinical trial and global markets, and is therefore very important for us, says Faron's CEO **Markku Jalkanen**. Rentschler has a long history with IFN-beta manufacturing and formulation development, and is therefore the most optimal Partner for Faron, continues Jalkanen.

About Faron Pharmaceuticals, Ltd.: Faron is a virtual drug discovery and development company with three major drug development projects focusing on acute traumas, incipient vasculopathies, inflammatory diseases, and cancer growth and metastasis. Faron's lead product Traumakine® is currently in the phase I/II study in UK to treat vascular leakage in ALI/ARDS patients.

Further information:

Markku Jalkanen, CEO
Phone: +358-40-520-6124
E-mail: markku.jalkanen@faronpharmaceuticals.com
www.faronpharmaceuticals.com